Format

Send to

Choose Destination
Dis Model Mech. 2014 Jun;7(6):613-23. doi: 10.1242/dmm.013904. Epub 2014 Apr 17.

Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease.

Author information

1
Oncology Research Unit, Pfizer Global Research and Development, San Diego, CA 92121, USA.
2
Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic. Bioinformatics Core Facility, SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.
3
Division of Gastroenterology, Tufts Medical Center, Boston, MA 02111, USA.
4
The Beatson Institute for Cancer Research, Garscube Estate, Glasgow, G61 1BD, UK.
5
Bioinformatics Core Facility, SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.
6
University Hospital Gasthuisberg, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
7
Pfizer Biotherapeutics Clinical Research, Cambridge, 02140 MA, USA.
8
Oncology Research Unit, Pfizer Global Research and Development, San Diego, CA 92121, USA. esmartin.phd@gmail.com.

Abstract

Effective treatment options for advanced colorectal cancer (CRC) are limited, survival rates are poor and this disease continues to be a leading cause of cancer-related deaths worldwide. Despite being a highly heterogeneous disease, a large subset of individuals with sporadic CRC typically harbor relatively few established 'driver' lesions. Here, we describe a collection of genetically engineered mouse models (GEMMs) of sporadic CRC that combine lesions frequently altered in human patients, including well-characterized tumor suppressors and activators of MAPK signaling. Primary tumors from these models were profiled, and individual GEMM tumors segregated into groups based on their genotypes. Unique allelic and genotypic expression signatures were generated from these GEMMs and applied to clinically annotated human CRC patient samples. We provide evidence that a Kras signature derived from these GEMMs is capable of distinguishing human tumors harboring KRAS mutation, and tracks with poor prognosis in two independent human patient cohorts. Furthermore, the analysis of a panel of human CRC cell lines suggests that high expression of the GEMM Kras signature correlates with sensitivity to targeted pathway inhibitors. Together, these findings implicate GEMMs as powerful preclinical tools with the capacity to recapitulate relevant human disease biology, and support the use of genetic signatures generated in these models to facilitate future drug discovery and validation efforts.

KEYWORDS:

BRAF; Colorectal cancer; GEMM; Genomic signatures; KRAS; MAPK

PMID:
24742783
PMCID:
PMC4036469
DOI:
10.1242/dmm.013904
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center